Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.11 is 87% above its 5-year average of -0.87, near the high end of its 5-year range (-2.53–-0.02).
37.29% above its 12-month average of -0.18.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.03.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 37 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.11
EARNINGS PER SHARE (EPS) AVG TTM
-0.18
EARNINGS PER SHARE (EPS) AVG 3Y
-0.30
EARNINGS PER SHARE (EPS) AVG 5Y
-0.87
EARNINGS PER SHARE (EPS) AVG 10Y
-1.52
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+37.29%
CURRENT VS 3Y AVG
+63.66%
CURRENT VS 5Y AVG
+87.36%
CURRENT VS 10Y AVG
+92.76%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Akebia Therapeutics, Inc.
Market Cap
$244.25M
Earnings Per Share (EPS)
-0.11
TTM Avg
-0.18
3Y Avg
-0.30
5Y Avg
-0.87
Market Cap
$245.65M
Earnings Per Share (EPS)
-0.43
TTM Avg
-0.62
3Y Avg
-0.66
5Y Avg
-0.59
Market Cap
$247.45M
Earnings Per Share (EPS)
-0.57
TTM Avg
-0.79
3Y Avg
-0.77
5Y Avg
-0.98
Market Cap
$248.21M
Earnings Per Share (EPS)
-1.54
TTM Avg
-1.32
3Y Avg
-0.98
5Y Avg
-0.74
Market Cap
$239.89M
Earnings Per Share (EPS)
-0.28
TTM Avg
-0.24
3Y Avg
-0.42
5Y Avg
-0.45
Market Cap
$239.45M
Earnings Per Share (EPS)
-2.38
TTM Avg
-2.11
3Y Avg
-1.81
5Y Avg
-1.81
Market Cap
$251.64M
Earnings Per Share (EPS)
-2.23
TTM Avg
-2.66
3Y Avg
-2.57
5Y Avg
-2.57
Market Cap
$236.56M
Earnings Per Share (EPS)
-3.17
TTM Avg
-5.64
3Y Avg
-13.77
5Y Avg
-18.37
Market Cap
$259.30M
Earnings Per Share (EPS)
-0.99
TTM Avg
-0.90
3Y Avg
-0.84
5Y Avg
-0.86
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | $244.25M | -0.11 | -0.18 | -0.30 | -0.87 |
| Galectin Therapeutics Inc. (GALT)vs › | $245.65M | -0.43 | -0.62 | -0.66 | -0.59 |
| InflaRx N.V. (IFRX)vs › | $247.45M | -0.57 | -0.79 | -0.77 | -0.98 |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $248.21M | -1.54 | -1.32 | -0.98 | -0.74 |
| High Tide Inc. (HITI)vs › | $239.89M | -0.28 | -0.24 | -0.42 | -0.45 |
| BioAge Labs Inc. (BIOA)vs › | $239.45M | -2.38 | -2.11 | -1.81 | -1.81 |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $251.64M | -2.23 | -2.66 | -2.57 | -2.57 |
| Biodesix, Inc. (BDSX)vs › | $236.56M | -3.17 | -5.64 | -13.77 | -18.37 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.30M | -0.99 | -0.90 | -0.84 | -0.86 |
| Anika Therapeutics, Inc. (ANIK)vs › | $264.05M | -0.27 | -2.29 | -2.81 | -2.11 |
Trailing EPS (TTM)
$-0.11
Forward EPS (Est.)
$-0.14
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.02 |
| 2024-12-31 | -0.33 |
| 2023-12-31 | -0.28 |
| 2022-12-31 | -0.58 |
| 2021-12-31 | -1.48 |
| 2020-12-31 | -2.53 |
| 2019-12-31 | -2.36 |
| 2018-12-31 | -1.47 |
| 2017-12-31 | -1.77 |
| 2016-12-31 | -3.60 |
| 2015-12-31 | -2.29 |
| 2014-12-31 | -2.40 |
| 2013-12-31 | -0.68 |
| 2012-12-31 | -0.81 |
